Clinical AI / Speech data

High-fidelity speech data for ambient clinical AI

HIPAA Safe Harbor de-identification, GDPR Article 9 biometric handling, EU AI Act Annex III item 5 evidence. 100% human verification across 150+ languages. BAA-ready for US Covered Entities.

Request a clinical sample dataset Read the methodology

Norwegian company · EEA-only operations · BAA addendum included with every US engagement

Clinical QA

100%

Human-in-the-loop verification. No automated pre-labeling on clinical audio. Native-speaker review across 150+ languages.

Language coverage

150+

Native-speaker coverage with deep Nordic dialectology (NO, SV, DA, FI) for European clinical AI builders.

Consent chain

5-stage

Cryptographically auditable: Speaker Consent to Agent Decision. GDPR Article 9 explicit-consent compliant.

BAA

Ready

Enterprise BAA-ready under HIPAA 45 CFR 164.502(e). Routinely signed with US Covered Entities.

Where clinical AI procurement breaks

Three failure modes the standard speech-data stack cannot fix

Procuring clinical speech data from an ambient-AI marketplace or an unmanaged cloud transcription API introduces three structural risks. Each block names the statute, the failure, and the structural answer.

EU AI Act Art. 10(3) + Clinical safety

Clinical Fidelity Gap

Automated pre-labeling on regional accents and specialty clinical lexicons produces hallucinations that cause 90-day adoption failure for ambient scribes. A wrong medication dose risks catastrophic patient harm. YPAI applies 100% human-in-the-loop QA across 150+ languages with deep Nordic dialectology; native speakers verify clinical context before delivery.

HIPAA 45 CFR 164.514 + EU AI Act Annex III.5

Regulatory Liability Chasm

HHS OCR 2026 penalties cap at 2,190,294 USD annually with Tier 4 willful-neglect floors of 73,011 USD per violation. Vendors that treat voice as text fail HIPAA 45 CFR 164.514 Safe Harbor (voice prints are identifier P). EU AI Act Annex III item 5 demands data-governance evidence. YPAI ships HIPAA Safe Harbor 18-identifier scrub with human verification plus EU AI Act Article 10 bias mitigation per project.

GDPR Art. 9 + EU MDR + AI Act Art. 6(1)

Provenance + Pipeline Bottleneck

Undocumented consent triggers GDPR Article 17 erasure mid-training and forces model recalibration. EU MDR Class IIa+ devices and EU AI Act Article 6(1) demand provenance for dual-conformity assessment. YPAI ships a 5-stage cryptographic consent chain that links Speaker Consent to Agent Decision, with EEA-only residency and no offshore sub-contracting.

Why it matters

Clinical AI procurement decisions made today carry 2026 enforcement and patient-safety liability.

EU AI Act Annex III item 5 enforcement begins 2 August 2026 with fines reaching 15 million EUR or 3% of global turnover for Article 10 data-governance breaches. HHS OCR 2026 penalty tier (effective 28 January 2026) caps annual liability at 2.19 million USD with willful-neglect floors of 73,011 USD per violation. A 90-day ambient-scribe adoption failure on regional accents or clinical lexicons is not a vendor problem; it is a clinician-burnout incident and a board-level KPI miss.

METHODOLOGY

From consent-gated capture to BAA-bound delivery

Five clinical pipeline stages, each anchored to a statute. Every dataset ships with the audit-trail bundle a HHS OCR investigator or EU notified body can open without follow-up.

  1. 01 GDPR Art. 9 + HIPAA 164.514(b)(2)

    PHI + biometric capture (consent-gated)

    Secure ingestion to EEA-quarantined environment. Raw clinical voice handled as GDPR Article 9 biometric special-category data. Explicit consent specifically for AI training.

  2. 02 HIPAA 45 CFR 164.514(b)(2)

    Safe Harbor de-identification + masking

    Human-led 18-identifier scrub including voice prints (item P) and unique characteristics (item R). No automated redaction-only. Verified against the Safe Harbor standard.

  3. 03 EU AI Act Art. 10(3)

    100% human-in-the-loop annotation

    Native speakers across 150+ languages with deep Nordic dialectology execute clinical transcription, ICD/SNOMED code grounding, and dialect verification. No automated pre-labeling.

  4. 04 EU AI Act Art. 10 + 11 + 12

    Cryptographic audit-trail generation

    5-stage consent chain documentation: Speaker Consent through Annotation Provenance to Agent Decision. EU AI Act conformity-assessment ready, Annex IV technical-documentation trace.

  5. 05 HIPAA 164.502(e) + EU MDR + EU AI Act

    Enterprise BAA-bound delivery

    Datasets transferred under an active Business Associate Agreement for US Covered Entities; DPA for EU controllers. Article 10 bias-mitigation report, MDR-AI Act dual-conformity provenance, OCR Risk Analysis extract included.

REGULATORY MATRIX

Every clinical claim mapped to a statute and a structural commitment

CCOs, legal, and clinical data leads can verify each line below against the standard BAA addendum, included with every US engagement, and the DPA, included with every EU engagement.

Compliance imperative Regulatory framework Standard-vendor failure What YPAI delivers
Imperative Voice data classification
Framework GDPR Art. 9
Standard-vendor failure Treats voice as standard text or PII; misses biometric special-category status.
YPAI delivers Recognised as biometric special-category data; explicit consent recorded.
Imperative De-identification standard
Framework HIPAA 45 CFR 164.514(b)(2)
Standard-vendor failure Automated redaction with high error rate on regional accents.
YPAI delivers 100% human verification of all 18 Safe Harbor identifiers, including voice prints (item P).
Imperative High-risk AI data governance
Framework EU AI Act Annex III item 5
Standard-vendor failure Unverifiable sourcing and provenance.
YPAI delivers Documented data quality, diversity, and bias mitigation per project.
Imperative Dual MDR + AI Act compliance
Framework EU MDR Class IIa+ + AI Act Art. 6(1)
Standard-vendor failure Ignored; assumes software unregulated.
YPAI delivers Data provenance for joint MDR / AI Act conformity assessment.
Imperative Auditable data provenance
Framework EU AI Act Art. 10 + 11 + 12
Standard-vendor failure Implied consent, untraceable origin.
YPAI delivers 5-stage cryptographic consent chain: Speaker Consent to Agent Decision.
Imperative Legal subcontractor risk
Framework HIPAA 45 CFR 164.502(e)
Standard-vendor failure Refuses to sign BAA, operates offshore with unclear flow-down.
YPAI delivers Enterprise BAA-ready; subcontractor flow-down liability accepted for US Covered Entities.
Imperative Data residency + sovereignty
Framework EU data sovereignty + GDPR Chapter V
Standard-vendor failure Globally distributed processing across multiple jurisdictions.
YPAI delivers EEA-only operations; data never leaves European jurisdiction.
Imperative Clinical dialectology
Framework EU AI Act Art. 10 + clinical safety
Standard-vendor failure Machine-translated or English-only training data.
YPAI delivers Native speakers across 150+ languages with deep Nordic dialectology (NO, SV, DA, FI).

Next steps

Related surfaces a clinical AI procurement team typically reviews

Clinical procurement FAQ

What CCO, CMIO, and clinical data leads ask first

How does YPAI legally process voice as biometric special-category data under GDPR Article 9?

Through a 5-stage consent chain. Each speaker provides explicit consent specifically for AI training under GDPR Article 9(2)(a), recorded with timestamp, purpose, and retention terms. The chain links Speaker Consent through Annotation Provenance to Agent Decision, cryptographically auditable end to end. No legitimate-interest fallback for clinical voice; explicit consent is the only lawful basis.

We are a US Covered Entity. How does a Norwegian vendor sign a BAA?

HIPAA permits international Business Associates if a valid BAA is executed under 45 CFR 164.502(e). YPAI is HIPAA-aware and routinely signs BAAs with US Covered Entities. GDPR is stricter than HIPAA on most controls, which simplifies the dual-compliance footprint: a YPAI engagement that satisfies our standard DPA generally satisfies HIPAA Safe Harbor too. The BAA addendum is included with every US engagement.

Why do you not hold SOC 2, ISO 27001, or an official HIPAA certification?

HHS does not actually offer a HIPAA certification; commercial "HIPAA-certified" badges are marketing. SOC 2 and ISO 27001 are US-centric IT controls aimed at general enterprise hosting, not the 2026 EU healthcare-AI regulatory environment. YPAI is engineered for HIPAA Safe Harbor (45 CFR 164.514), GDPR Article 9, EU AI Act Annex III item 5, and EU MDR dual-conformity. The compliance match is operational and statutory, not certification-driven.

How is YPAI preparing for EU AI Act Annex III item 5 enforcement on 2 August 2026?

Annex III item 5 classifies healthcare AI as high-risk; Article 10 demands data-quality and bias-mitigation evidence. YPAI ships an Article 10 bias-mitigation report with every project: representativeness against the deployment population, bias variance across age and accent and dialect and clinical specialty, plus the Article 11 + 12 technical-documentation trace. Delivered with the dataset, not on request. For SaMD Class IIa+, the same dataset supports the MDR conformity assessment.

Why insist on 100% human-in-the-loop QA when automated pre-labeling is faster?

Automated pre-labeling introduces algorithmic bias and clinical hallucination. On clinical audio, the failure modes are not benign: misheard medication doses, misclassified ICD codes, misattributed speaker identity. Human verification establishes ground truth that the downstream foundation model can actually trust. Faster delivery on a hallucinating dataset is a 90-day adoption-failure incident, not a win.

Clinical data project intake

Scope a clinical speech-data project

Bring the model objective, target jurisdiction (US, EU, or both), therapeutic areas, and language cohorts. We map the first BAA-bound or DPA-bound data path with your CCO, CMIO, and clinical data lead.

  • HIPAA Safe Harbor verified by humans

    100% human verification of all 18 Safe Harbor identifiers, including voice prints and unique characteristics.

  • BAA-ready for US Covered Entities

    Enterprise BAA addendum executed under 45 CFR 164.502(e); subcontractor flow-down liability accepted.

  • GDPR Article 9 explicit consent

    5-stage cryptographic consent chain; no legitimate-interest fallback for clinical voice.

  • EU AI Act Annex III evidence

    Article 10 bias-mitigation report and Article 11 + 12 technical-documentation trace per project.